Skip to main content

Table 4 Incidence of adverse events (N = 93)

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Adverse event

≥Grade 1

≥Grade 3

N

%

N

%

Neutropenia

89

95.7

56

60.2

Leukopenia

89

95.7

22

23.7

Thrombocytopenia

12

12.9

0

0

Anemia

44

47.3

7

7.5

AST

27

29.0

0

0

ALT

32

34.4

1

1.1

Anorexia

60

64.5

6

6.5

Diarrhea

59

63.4

9

9.7

Nausea

61

65.6

0

0

Stomatitis

62

66.7

3

3.2

Vomiting

36

38.7

0

0

Fatigue

66

71.0

5

5.4

Cholinergic syndrome

18

19.4

0

0

Febrile neutropenia

1

1.1

1

1.1

Sepsis

2

2.2

2

2.2

Interstitial pneumonia

1

1.1

0

0

Hypertension

10

10.8

1

1.1

Bleeding

7

7.5

0

0

Pulmonary artery thrombosis

1

1.1

1

1.1

Pulmonary embolism

1

1.1

0

0

Embolism venous

1

1.1

1

1.1

Gastrointestinal perforation

2

2.2

2

2.2